Efficacy and Tolerability of Intravenous Ferric Carboxymaltose in Patients with Iron Deficiency at a Hospital Outpatient Clinic: A Retrospective Cohort Study of Real-World Clinical Practice
Ferric carboxymaltose (FCM) is an intravenous iron formulation to correct iron deficiency. Although its use has been extensively studied in clinical trials, real-world evidence regarding FCM treatment is scarce. Our aim was to evaluate the efficacy and tolerability of FCM treatment in patients with...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Anemia |
| Online Access: | http://dx.doi.org/10.1155/2017/3106890 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550051086336000 |
|---|---|
| author | António Robalo Nunes Ana Palricas Costa Sara Lemos Rocha Ana Garcia de Oliveira |
| author_facet | António Robalo Nunes Ana Palricas Costa Sara Lemos Rocha Ana Garcia de Oliveira |
| author_sort | António Robalo Nunes |
| collection | DOAJ |
| description | Ferric carboxymaltose (FCM) is an intravenous iron formulation to correct iron deficiency. Although its use has been extensively studied in clinical trials, real-world evidence regarding FCM treatment is scarce. Our aim was to evaluate the efficacy and tolerability of FCM treatment in patients with iron deficiency, with or without anemia, at a hospital outpatient clinic. Data was collected retrospectively from medical records. During this 2-year study, 459 patients were included. Mean age was 58.6 ± 17.5 years and most patients received cumulative FCM doses of 501–1000 mg (63.2%). Six weeks after administration of FCM, efficacy endpoints hemoglobin increase ≥2 g/dL, hemoglobin increase ≥3 g/dL, and transferrin saturation > 20% were attained by 41%, 20%, and 63% of patients, respectively. Patients who received higher FCM doses showed significant reduced odds of not achieving hemoglobin increase ≥2 g/dL (501–1000 mg, adjusted odds ratio [OR]: 0.34, 95% confidence interval [CI] 0.18–0.62; 1001–3000 mg, OR: 0.19, 95% CI 0.07–0.49), compared to 500 mg doses. Treatment-emergent adverse events were documented in <4% of patients. In conclusion, FCM treatment was effective and well-tolerated by outpatients with iron deficiency at a hospital clinic, and its dosage should be adjusted to improve iron deficiency management in clinical practice. |
| format | Article |
| id | doaj-art-2912b6eedbe14e35af0a4f24c248f2ba |
| institution | Kabale University |
| issn | 2090-1267 2090-1275 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Anemia |
| spelling | doaj-art-2912b6eedbe14e35af0a4f24c248f2ba2025-02-03T06:07:45ZengWileyAnemia2090-12672090-12752017-01-01201710.1155/2017/31068903106890Efficacy and Tolerability of Intravenous Ferric Carboxymaltose in Patients with Iron Deficiency at a Hospital Outpatient Clinic: A Retrospective Cohort Study of Real-World Clinical PracticeAntónio Robalo Nunes0Ana Palricas Costa1Sara Lemos Rocha2Ana Garcia de Oliveira3Hospital de Dia de Imuno-Hemoterapia, Hospital Pulido Valente, Centro Hospitalar Lisboa Norte (CHLN), Alameda das Linhas de Torres 117, 1769-001 Lisboa, PortugalHospital de Dia de Imuno-Hemoterapia, Hospital de Santa Maria, CHLN, Avenida Prof. Egas Moniz, 1649-035 Lisboa, PortugalHospital de Dia de Imuno-Hemoterapia, Hospital de Santa Maria, CHLN, Avenida Prof. Egas Moniz, 1649-035 Lisboa, PortugalHospital de Dia de Imuno-Hemoterapia, Hospital de Santa Maria, CHLN, Avenida Prof. Egas Moniz, 1649-035 Lisboa, PortugalFerric carboxymaltose (FCM) is an intravenous iron formulation to correct iron deficiency. Although its use has been extensively studied in clinical trials, real-world evidence regarding FCM treatment is scarce. Our aim was to evaluate the efficacy and tolerability of FCM treatment in patients with iron deficiency, with or without anemia, at a hospital outpatient clinic. Data was collected retrospectively from medical records. During this 2-year study, 459 patients were included. Mean age was 58.6 ± 17.5 years and most patients received cumulative FCM doses of 501–1000 mg (63.2%). Six weeks after administration of FCM, efficacy endpoints hemoglobin increase ≥2 g/dL, hemoglobin increase ≥3 g/dL, and transferrin saturation > 20% were attained by 41%, 20%, and 63% of patients, respectively. Patients who received higher FCM doses showed significant reduced odds of not achieving hemoglobin increase ≥2 g/dL (501–1000 mg, adjusted odds ratio [OR]: 0.34, 95% confidence interval [CI] 0.18–0.62; 1001–3000 mg, OR: 0.19, 95% CI 0.07–0.49), compared to 500 mg doses. Treatment-emergent adverse events were documented in <4% of patients. In conclusion, FCM treatment was effective and well-tolerated by outpatients with iron deficiency at a hospital clinic, and its dosage should be adjusted to improve iron deficiency management in clinical practice.http://dx.doi.org/10.1155/2017/3106890 |
| spellingShingle | António Robalo Nunes Ana Palricas Costa Sara Lemos Rocha Ana Garcia de Oliveira Efficacy and Tolerability of Intravenous Ferric Carboxymaltose in Patients with Iron Deficiency at a Hospital Outpatient Clinic: A Retrospective Cohort Study of Real-World Clinical Practice Anemia |
| title | Efficacy and Tolerability of Intravenous Ferric Carboxymaltose in Patients with Iron Deficiency at a Hospital Outpatient Clinic: A Retrospective Cohort Study of Real-World Clinical Practice |
| title_full | Efficacy and Tolerability of Intravenous Ferric Carboxymaltose in Patients with Iron Deficiency at a Hospital Outpatient Clinic: A Retrospective Cohort Study of Real-World Clinical Practice |
| title_fullStr | Efficacy and Tolerability of Intravenous Ferric Carboxymaltose in Patients with Iron Deficiency at a Hospital Outpatient Clinic: A Retrospective Cohort Study of Real-World Clinical Practice |
| title_full_unstemmed | Efficacy and Tolerability of Intravenous Ferric Carboxymaltose in Patients with Iron Deficiency at a Hospital Outpatient Clinic: A Retrospective Cohort Study of Real-World Clinical Practice |
| title_short | Efficacy and Tolerability of Intravenous Ferric Carboxymaltose in Patients with Iron Deficiency at a Hospital Outpatient Clinic: A Retrospective Cohort Study of Real-World Clinical Practice |
| title_sort | efficacy and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency at a hospital outpatient clinic a retrospective cohort study of real world clinical practice |
| url | http://dx.doi.org/10.1155/2017/3106890 |
| work_keys_str_mv | AT antoniorobalonunes efficacyandtolerabilityofintravenousferriccarboxymaltoseinpatientswithirondeficiencyatahospitaloutpatientclinicaretrospectivecohortstudyofrealworldclinicalpractice AT anapalricascosta efficacyandtolerabilityofintravenousferriccarboxymaltoseinpatientswithirondeficiencyatahospitaloutpatientclinicaretrospectivecohortstudyofrealworldclinicalpractice AT saralemosrocha efficacyandtolerabilityofintravenousferriccarboxymaltoseinpatientswithirondeficiencyatahospitaloutpatientclinicaretrospectivecohortstudyofrealworldclinicalpractice AT anagarciadeoliveira efficacyandtolerabilityofintravenousferriccarboxymaltoseinpatientswithirondeficiencyatahospitaloutpatientclinicaretrospectivecohortstudyofrealworldclinicalpractice |